Jazz Pharmaceuticals (JAZZ) Competitors

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Axsome Therapeutics (NASDAQ:AXSM) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings.

Does the media refer more to JAZZ or AXSM?

In the previous week, Jazz Pharmaceuticals had 8 more articles in the media than Axsome Therapeutics. MarketBeat recorded 18 mentions for Jazz Pharmaceuticals and 10 mentions for Axsome Therapeutics. Jazz Pharmaceuticals' average media sentiment score of 0.83 beat Axsome Therapeutics' score of 0.51 indicating that Jazz Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jazz Pharmaceuticals	10 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Axsome Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Do analysts prefer JAZZ or AXSM?

Jazz Pharmaceuticals presently has a consensus price target of $181.64, indicating a potential upside of 54.14%. Axsome Therapeutics has a consensus price target of $172.33, indicating a potential upside of 65.76%. Given Axsome Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Axsome Therapeutics is more favorable than Jazz Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jazz Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.93
Axsome Therapeutics	0 Sell rating(s)	0 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	3.06

Is JAZZ or AXSM more profitable?

Jazz Pharmaceuticals has a net margin of 11.86% compared to Axsome Therapeutics' net margin of -64.39%. Jazz Pharmaceuticals' return on equity of 26.62% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jazz Pharmaceuticals	11.86%	26.62%	9.14%
Axsome Therapeutics	-64.39%	-272.80%	-36.69%

Which has more risk and volatility, JAZZ or AXSM?

Jazz Pharmaceuticals has a beta of 0.32, meaning that its share price is 68% less volatile than the S&P 500. Comparatively, Axsome Therapeutics has a beta of 0.46, meaning that its share price is 54% less volatile than the S&P 500.

Which has better valuation & earnings, JAZZ or AXSM?

Jazz Pharmaceuticals has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jazz Pharmaceuticals	$4.07B	1.75	$560.12M	$7.50	15.71
Axsome Therapeutics	$385.69M	13.27	-$287.22M	-$5.77	-18.02

Do insiders & institutionals believe in JAZZ or AXSM?

89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are owned by institutional investors. 4.3% of Jazz Pharmaceuticals shares are owned by company insiders. Comparatively, 22.4% of Axsome Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Jazz Pharmaceuticals beats Axsome Therapeutics on 10 of the 17 factors compared between the two stocks.